The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Proton Pump Inhibitor Use and Risk of Colorectal Cancer: A Population-Based, Case–Control Study
Abstract
Background & aims Use of proton pump inhibitors (PPIs) has been associated with elevated levels of serum gastrin. Because hypergastrinemia increases colorectal mucosa proliferation and has been associated with risk of colorectal cancer (CRC) in human beings, we conducted a large population-based study in Denmark to assess whether PPI use is associated with CRC risk.Methods We conducted the study in North Jutland County, Denmark. From the County Hospital Discharge Registry we identified incident cases of CRC during the period 1989-2005. Using risk set sampling we selected approximately 10 controls from the Danish Civil Registration System, with matching for sex and birth year. PPI use was ascertained in the Prescription Database of North Jutland (and so recorded before CRC diagnosis) and analyzed with conditional logistic regression adjusted for multiple covariates.Results We identified 5589 cases of CRC which were compared with 55,890 controls. In a comparison of ever to never or rare users (< or =30 pills during observation period), no evidence was observed of increased risk (adjusted odds ratio [OR], 1.11; 95% confidence interval [CI], 0.97-1.27). When we compared the most intense users of PPI (more than every other day) with never or rare users, we found that no increased cancer risk was shown in either short-term users (adjusted OR, 1.07; 95% CI, 0.86-1.34) or long-term users (>7 years; adjusted OR = 1.09; 95% CI, 0.58-2.06).Conclusions The use of PPIs in clinical practice does not measurably increase the risk of CRC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, it is fundamental to highlight that many studies over the years have not found a direct correlation between PPI use in clinical practice and an increased risk of CRC[154-156].”
From Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified (2019) · cites this paper as [156]
Citations
Cites
The Danish National Hospital Register. A valuable source of data for modern health sciences.
Andersen, T. F., Madsen, M., Jørgensen, J. O. L., Mellemkjoer, L., & Olsen, J. H. (1999) · PubMed · Cited by 2,026
Epidemiology: Beyond the Basics
Szklo, M., & Nieto, F. J. (1999) · Cited by 1,441
Epidemiology: Beyond the Basics
Szklo, M. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.8.821 · Cited by 1,320
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yang, Y., Lewis, J. D., Epstein, S., & Metz, D. C. (2006) · JAMA · doi:10.1001/jama.296.24.2947 · Cited by 1,210
Selection of Controls in Case-Control Studies
Wacholder, S., McLaughlin, J. K., Silverman, D. T., & Mandel, J. S. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116396 · Cited by 998
The Danish prescription registries.
Gaist, D., Sørensen, H. T., & Hallas, J. (1997) · PubMed · Cited by 570
Self-citationApproaches to nonsteroidal anti-inflammatory drug use in the high-risk patient
Laine, L. (2001) · Gastroenterology · doi:10.1053/gast.2001.21907 · Cited by 551
A Comparison of Five Maintenance Therapies for Reflux Esophagitis
Vigneri, S., Termini, R., Leandro, G., Badalamenti, S., Pantalena, M., Savarino, V., Mario, F. D., Battaglia, G., Mela, G. S., Pilotto, A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331703 · Cited by 539
Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer
Chan, A. T. (2005) · JAMA · doi:10.1001/jama.294.8.914 · Cited by 479
The Pharmacology of the Gastric Acid Pump: The H+,K+ ATPase
Sachs, G. M., Shin, J. M., Briving, C., Wallmark, B., & Hersey, S. J. (1995) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.001425 · Cited by 368
Wolfe, M. M., & Sachs, G. M. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70004-7 · Cited by 350
Processing and proliferative effects of human progastrin in transgenic mice.
Wang, T. C., Koh, T. J., Varró, A., Cahill, R., Dangler, C. A., Fox, J. G., & Dockray, G. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118993 · Cited by 299
Ulcer Prevention in Long-term Users of Nonsteroidal Anti-inflammatory Drugs
Graham, D. Y., Agrawal, N. M., Campbell, D. R., Haber, M. M., Collis, C., Lukasik, N. L., & Huang, B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.2.169 · Cited by 299
Gastrin and colorectal cancer: A prospective study
Thorburn*, C. M., Friedman‡, G. D., Dickinson§, C. J., Vogelman∥, J. H., Orentreich∥, N., & Parsonnet*, #. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70193-3 · Cited by 267
Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.
Sharma, B. K., Walt, R. P., Pounder, R. E., Gomes, M. D., Wood, E. C., & Logan, L. H. (1984) · Gut · doi:10.1136/gut.25.9.957 · Cited by 240
Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study
Sørensen, H. T., Friis, S., Nørgård, B. M., Mellemkjær, L., Blot, W. J., McLaughlin, J. K., Ekbom, A., & Baron, J. A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600945 · Cited by 221
Self-citationEissele, R., Brunner, G. H. G., Simon, B., Solcia, E., & Arnold, R. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9041231 · Cited by 205
Rodríguez, L. A. G., Lagergren, J., & Lindblad, M. (2006) · Gut · doi:10.1136/gut.2005.086579 · Cited by 203
Effects of Gastrin, Proglumide, and Somatostatin on Growth of Human Colon Cancer
Smith, J. P., & Solomon, T. E. (1988) · Gastroenterology · doi:10.1016/s0016-5085(88)80075-1 · Cited by 166
Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding
Leontiadis, G. I., Sharma, V. K., & Howden, C. W. (2005) · BMJ · doi:10.1136/bmj.38356.641134.8f · Cited by 163
Koh, T. J., Dockray, G. J., Varró, A., Cahill, R., Dangler, C. A., Fox, J. G., & Wang, T. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4910 · Cited by 161
Hoosein, N. M., Kiener, P. A., Curry, R. C., Rovati, L. C., McGilbra, D. K., & Brattain, M. G. (1988) · PubMed · Cited by 146
Gastrins, cholecystokinins and gastrointestinal cancer
Aly, A., Shulkes, A., & Baldwin, G. S. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.01.004 · Cited by 144
Descriptive tools and analysis.
Capellà, D. (1993) · PubMed · Cited by 127
Jansen, J. B. �. �., Klinkenberg–Knol, E. C., Meuwissen, S. G. M., de Bruijne, J. W., Festen, H. P. M., Snel, P., Ae, L., Biemond, I., & Lamers, C. B. H. W. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90946-x · Cited by 116
Proton pump inhibitors and gastric neoplasia: Figure 1
Kuipers, E. J. (2006) · Gut · doi:10.1136/gut.2005.090514 · Cited by 115
Beauchamp, R. D., Townsend, C. M., Singh, P., Glass, E. J., & Thompson, J. C. (1985) · Annals of Surgery · doi:10.1097/00000658-198509000-00005 · Cited by 114
The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin
Watson, S. A., Durrant, L. G., Crosbie, J., & Morris, D. L. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430425 · Cited by 106
Elevated gastrin levels in patients with colon cancer or adenomatous polyps
Smith, J. P., Wood, J. G., & Solomon, T. E. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01536047 · Cited by 104
Smith, A. M., & Watson, S. A. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00842.x · Cited by 98
Nielsen, G. L., Sørensen, H. T., Zhou, W., Steffensen, F. H., & Olsen, J. (1997) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-1997-10309 · Cited by 89
Self-citationMortality study of 18 000 patients treated with omeprazole
Bateman, D. N., Colin-Jones, D. G., Hartz, S. C., Langman, M. J. S., Logan, R. F., Mant, J., Murphy, M., Paterson, K. R., Rowsell, R., Thomas, S., et al. (2003) · Gut · doi:10.1136/gut.52.7.942 · Cited by 78
Salas, M., Ward, A., & Jaime, J. (2002) · BMC Gastroenterology · doi:10.1186/1471-230x-2-17 · Cited by 77
Patterns of proton pump inhibitor use in clinical practice
Barrison, A. F., Jarboe, L. A., Weinberg, B. M., Nimmagadda, K., SULLIVAN, L. M., & Wolfe, M. M. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00901-9 · Cited by 77
Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia
Renga, M., Brandi, G., Paganelli, G. M., Calabrese, C., Papa, S., Tosti, A., Tomassetti, P., Miglioli, M., & Biasco, G. (1997) · Gut · doi:10.1136/gut.41.3.330 · Cited by 66
Johnsen, S. P., Pedersen, L. H., Friis, S., Blot, W. J., McLaughlin, J. K., Olsen, J. H., & Sørensen, H. T. (2003) · Stroke · doi:10.1161/01.str.0000054057.11892.5b · Cited by 61
Self-citationPenman, I. D., El-Omar, E. M., Ardill, J. E. S., McGregor, J. R., Galloway, D., O’Dwyer, P. J., & McColl, K. E. L. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90018-3 · Cited by 60
Omeprazole, Hypergastrinemia, and Gastric Carcinoid Tumors
Freston, J. W. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-3-199408010-00012 · Cited by 60
Postprandial hypergastrinaemia in patients with colorectal cancer.
Wong, K., Beardshall, K., Waters, C., Calam, J., & Poston, G. J. (1991) · Gut · doi:10.1136/gut.32.11.1352 · Cited by 60
Elevated Serum Gastrin Levels in Patients with Colorectal Neoplasia
Seitz, E., Giovannini, M. F., Gouvernet, J., & Gautheir, A. P. (1991) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199110000-00013 · Cited by 58
Trends in colorectal cancer survival in northern Denmark: 1985–2004
Iversen, L. H., Nørgaard, M., Jepsen, P., Jacobsen, J. B., Christensen, M. M., Gandrup, P., Madsen, M. R., Laurberg, S., Wogelius, P., Sørensen, H. T., et al. (2006) · Colorectal Disease · doi:10.1111/j.1463-1318.2006.01130.x · Cited by 58
Self-citationSerum levels of gastrin in patients with colorectal neoplasia
Suzuki, H., Matsumoto, K., & Terashima, H. (1988) · Diseases of the Colon & Rectum · doi:10.1007/bf02552592 · Cited by 52
Orbuch, M., Venzon, D. J., Lubensky, I. A., Weber, H. C., Gibril, F., & Jensen, R. T. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02282349 · Cited by 51
Considerations for long-term use of proton-pump inhibitors
Garnett, W. R. (1998) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/55.21.2268 · Cited by 50
Yapp, R. G., Modlin, I. M., Kumar, R. R., Binder, H. J., & Dubrow, R. (1992) · Digestive Diseases and Sciences · doi:10.1007/bf01307566 · Cited by 48
Siersema, P. D., Yu, S., Sahbaie, P., Steyerberg, E. W., Simpson, P. W., Kuipers, E. J., & Triadafilopoulos, G. (2006) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2005.08.043 · Cited by 47
Serum gastrin is not higher in subjects with colonic neoplasia.
Kikendall, J. W., Ar, G., Lh, S., & Bowen, P. E. (1992) · PubMed · Cited by 44
Session 5: Trophic Effects of Gastrin
Håkanson, R., & Sundler, F. (1991) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529109093190 · Cited by 43
Anti‐gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour AP5
Watson, S. A., Michaeli, D., Grimes, S., Morris, T. M., Crosbee, D. M., Wilkinson, M., Robinson, G., Robertson, J. F. R., Steele, R. J., & Hardcastle, J. D. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610216 · Cited by 34
A review of epidemiological studies on cancer in relation to the use of anti-ulcer drugs
Vecchia, C. L., & Tavani, A. (2002) · European Journal of Cancer Prevention · doi:10.1097/00008469-200204000-00002 · Cited by 29
Serum gastrin concentrations in colorectal cancer patients.
Charnley, R., Thomas, W. M., Stanley, J., & Morris, D. L. (1992) · PubMed Central · Cited by 18
Research works printed but not linked: 1
- Andersen, 1999, The Danish National Hospital Register, Dan Med Bull, 46, 263
Cited by
Sorted by citations
Freedberg, D. E., Kim, L. S., & Yang, Y. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.031 · Cited by 933
Control of Gastric Acid Secretion in Health and Disease
Schubert, M. L., & Peura, D. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.021 · Cited by 493
for the SIF-AIGO-FIMMG Group, Scarpignato, C., on behalf of the Italian Society of Pharmacology, T. I. A. O. H. G., Gatta, L., Zullo, A., & Blandizzi, C. (2016) · BMC Medicine · doi:10.1186/s12916-016-0718-z · Cited by 469
Proton pump inhibitors: an update of their clinical use and pharmacokinetics
Shi, S., & Klotz, U. E. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0538-y · Cited by 314
Adverse Effects of Long-Term Proton Pump Inhibitor Therapy
Sheen, E., & Triadafilopoulos, G. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1560-3 · Cited by 316
“Long-term PPI therapy at a regular dose was not associated with a significantly increased risk of CRC.”
BackgroundInfluential
Metadata
- Authors
- Robertson, D. J., Larsson, H., Friis, S., Pedersen, L., Baron, J. A., & Sørensen, H. T.
- Affiliations
- Dartmouth–Hitchcock Medical Center (US)
- Aarhus University Hospital (DK)
- Danish Cancer Society (DK)
- Corresponding author
- Robertson, Douglas J.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 133
- Issue
- 3
- Pages
- 755-760
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W1977659216
- Cited by
- 139
- References
- 51
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 1 · 2021: 9 · 2020: 17 · 2019: 3 · 2018: 7 · 2017: 10 · 2016: 5 · 2015: 5 · 2014: 3 · 2013: 7 · 2012: 8
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Keywords
- proton pump inhibitors, colorectal cancer, hypergastrinemia, serum gastrin, cancer risk, drug use, long-term PPI use
- MeSH terms
- Aged, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Denmark, Dose-Response Relationship, Drug, Female, Gastrins, Histamine H2 Antagonists, Humans, Hypoglycemic Agents, Intestinal Mucosa, Male, Risk Factors, Time Factors, Colorectal Neoplasms, Logistic Models, Case-Control Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cell Proliferation, Proton Pump Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review